• USFDA Inspection Clearance: Morepen Labs received its fourth consecutive USFDA clearance with zero Form 483 observations for its Himachal facility, driven by fully digitized audit and data-tracking systems.
• Facility Revenue Contribution: The prime Baddi facility currently generates approximately Rs 450 crore to Rs 500 crore in revenue, primarily from the production of Loratadine, Desloratadine, and Montelukast.
• CDMO Contract Ramp-up: Shipments for the Rs 825 crore overseas CDMO order will commence in July or August (Q2), contributing an estimated Rs 500 crore to Rs 600 crore to the existing Rs 900 crore to Rs 1,000 crore API revenue base.
• Revenue Growth Guidance: Management maintains a baseline year-on-year growth target of 15%, with expectations for API business growth to exceed 20% to 25% in FY27 supported by the new CDMO contract.